Pacira BioSciences, Inc. (PCRX)

Market Cap	1.14B
Revenue (ttm)	705.85M
Net Income (ttm)	-127.46M
Shares Out	44.93M
EPS (ttm)	-2.81
PE Ratio	n/a
Forward PE	8.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	399,348
Open	25.86
Previous Close	25.84
Day's Range	25.33 - 25.87
52-Week Range	12.61 - 27.64
Beta	0.48
Analysts	Buy
Price Target	30.00 (+18.3%)
Earnings Date	Aug 5, 2025

About PCRX

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled dos...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2011
• Employees: 790
• Stock Exchange: NASDAQ
• Ticker Symbol: PCRX
• Website: https://www.pacira.com

Analyst Summary

According to 6 analysts, the average rating for PCRX stock is "Buy." The 12-month stock price target is $30.0, which is an increase of 18.30% from the latest price.

Price Target

$30.0

(18.30% upside)

Analyst Consensus: Buy